LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Other Accrued Liabilities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Other Accrued Liabilities of $319.00 thousand for the 12-month period ending 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for the quarter ending 2024-05-26 was $519.00K.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for the quarter ending 2024-02-25 was $2.49M, a 57.09% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for the quarter ending 2023-11-26 was -$156.00K, a 106.01% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for the quarter ending 2023-08-27 was -$2.53M, a 1482.51% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for fiscal 2024 was $319.00K, a 91.99% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for fiscal 2023 was $3.98M.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for fiscal 2022 was -$873.00K, a 207.78% decline from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in other accrued liabilities for fiscal 2021 was $810.00K, a 35.87% decline from fiscal 2020.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accrued Liabilities 12 month | Increase (Decrease) in Other Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-05-26 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $3.00M derived: sum of 2 quarters · filed 2024-08-26 | $2.85M derived: sum of 3 quarters · filed 2024-08-26 | $319.00K 10-K · filed 2024-08-26 | ||||
| 2024-02-25 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $2.33M derived: sum of 2 quarters · filed 2024-08-09 | -$200.00K 10-Q · filed 2024-08-09 | -$4.79M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-11-26 | -$156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$2.69M 10-Q · filed 2024-08-09 | -$7.27M derived: sum of 3 quarters · filed 2024-08-26 | -$1.48M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-08-27 | -$2.53M 10-Q · filed 2024-08-09 | -$7.12M derived: sum of 2 quarters · filed 2024-08-26 | -$1.32M derived: sum of 3 quarters · filed 2024-08-26 | $1.27M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2023-05-28 | -$4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $1.21M derived: sum of 2 quarters · filed 2024-08-26 | $3.80M derived: sum of 3 quarters · filed 2024-08-26 | $3.98M 10-K · filed 2024-08-26 | $7.17M 10-K · filed 2024-03-20 | |||
| 2023-02-26 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $8.39M derived: sum of 2 quarters · filed 2024-08-09 | $8.57M 10-Q · filed 2024-08-09 | $7.77M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2022-11-27 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $2.78M 10-Q · filed 2024-08-09 | $1.97M derived: sum of 3 quarters · filed 2024-08-26 | $629.00K derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2022-08-28 | $183.00K 10-Q · filed 2024-08-09 | -$620.00K derived: sum of 2 quarters · filed 2024-08-26 | -$1.97M derived: sum of 3 quarters · filed 2024-08-26 | -$3.56M derived: sum of 4 quarters · filed 2024-08-26 | ||||
| 2022-05-29 | -$803.00K derived: 10-K 12 month − 10-K 9 month · filed 2024-08-26 | -$2.15M derived: sum of 2 quarters · filed 2024-08-26 | -$3.74M derived: sum of 3 quarters · filed 2024-08-26 | -$873.00K 10-K · filed 2024-08-26 | -$680.00K 10-K · filed 2022-09-14 | |||
| 2022-02-27 | -$1.34M derived: 10-K 9 month − 10-K 6 month · filed 2024-03-20 | -$2.94M derived: sum of 2 quarters · filed 2024-03-20 | -$70.00K 10-K · filed 2024-03-20 | -$4.20M 10-Q · filed 2022-04-07 | -$2.80M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-11-28 | -$1.59M derived: 10-K 6 month − 10-K 3 month · filed 2024-03-20 | $1.27M 10-K · filed 2024-03-20 | $1.16M 10-Q · filed 2022-01-07 | -$1.45M derived: sum of 3 quarters · filed 2024-03-20 | -$2.54M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-08-29 | $2.87M 10-K · filed 2024-03-20 | $2.84M 10-Q · filed 2021-10-05 | $144.00K derived: sum of 2 quarters · filed 2024-03-20 | -$947.00K derived: sum of 3 quarters · filed 2024-03-20 | $3.07M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2021-05-30 | -$2.73M derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | -$3.82M derived: sum of 2 quarters · filed 2024-03-20 | $197.00K derived: sum of 3 quarters · filed 2024-03-20 | $810.00K 10-K · filed 2024-03-20 | $460.00K 10-K · filed 2021-07-29 | |||
| 2021-02-28 | -$1.09M derived: 10-K 9 month − 10-Q 6 month · filed 2024-03-20 | $2.92M derived: sum of 2 quarters · filed 2024-03-20 | $3.54M 10-K · filed 2024-03-20 | $3.19M 10-Q · filed 2021-04-08 | $3.29M derived: sum of 4 quarters · filed 2024-03-20 | |||
| 2020-11-29 | $4.01M derived: 10-Q 6 month − 10-K 3 month · filed 2022-01-07 | $4.63M 10-Q · filed 2022-01-07 | $4.39M derived: sum of 3 quarters · filed 2024-03-20 | $4.75M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2020-08-30 | $613.00K 10-K · filed 2024-03-20 | $372.00K derived: sum of 2 quarters · filed 2024-03-20 | $731.00K derived: sum of 3 quarters · filed 2024-03-20 | $2.77M derived: sum of 4 quarters · filed 2024-03-20 | ||||
| 2020-05-31 | -$241.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $118.00K derived: sum of 2 quarters · filed 2023-03-16 | $2.16M derived: sum of 3 quarters · filed 2023-03-16 | $1.26M 10-K/A · filed 2023-03-16 | ||||
| 2020-02-23 | $359.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-08 | $2.40M derived: sum of 2 quarters · filed 2021-04-08 | $1.50M 10-Q · filed 2021-04-08 | |||||
| 2019-11-24 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-07 | $1.15M 10-Q · filed 2021-01-07 | ||||||
| 2019-08-25 | -$893.00K 10-Q · filed 2020-10-07 | |||||||
| 2019-05-26 | $21.00K 10-K · filed 2021-07-29 | |||||||
| 2018-05-27 | -$1.38M 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |